Common Atrial and Ventricular Arrhythmias

  • Blair Foreman
Part of the Contemporary Cardiology book series (CONCARD)


Cardiac arrhythmias and their clinical correlates form the basis for some of the most intriguing aspects of cardiac care. During training, however, emphasis is often placed on care related to congestive heart failure, myocardial infarction, and the treatment of dyslipidemias. Unfortunately, patient complaints related to cardiac arrhythmias are often a common reason for a patient’s presentation to emergency rooms, for office visits, and for referrals to subspecialists.


Arrhythmia ablation Antiarrhythmic drugs Atrial fibrillation Atrial flutter Ventricular tachycardia Sick sinus syndrome 


  1. 1.
    Josephson ME. Preexcitation syndromes. In: Clinical cardiac electrophysiology: techniques and interpretations. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 322–424.Google Scholar
  2. 2.
    Boyett MR, Honjo H, Kodama I. Review: the sinoatrial node, a heterogeneous pacemaker structure. Cardiovasc Res. 2000;47:658–87.CrossRefPubMedGoogle Scholar
  3. 3.
    Marriott HJL. Chamber enlargement. In: Practical electrocardiography. 7th ed. Baltimore: Williams and Wilkins; 1983. p. 58–9.Google Scholar
  4. 4.
    Daviddnko JM. Spiral waves in the heart: experimental demonstration of a theory. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology—from cell to bedside. 2nd ed. Philadelphia: W.B. Saunders; 1995. p. 478–87.Google Scholar
  5. 5.
    Desai JM, Scheinman MM, Strauss HC, et al. Electrophysiologic effects of combined autonomic blockade in patients with sinus node disease. Circulation. 1981;63:953–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Boineau JP, Canavan TE, Schuessler RB, et al. Demonstration of a widely distributed atrial pacemaker complex in the human heart. Circulation. 1988;77:1221–37.CrossRefPubMedGoogle Scholar
  7. 7.
    Boineau JP, Schuessler RB, Roeske WR, et al. Quantitative relation between sites of atrial muscle origin and cycle length. Am J Physiol. 1983;245:H781–9.PubMedGoogle Scholar
  8. 8.
    Mackeray AJC, Opthof T, Leeker WK, Jongsma HJ, Bouman LN. Interaction of adrenaline and acetylcholine on sinus node function. In: Bouman LN, Jongsma HJ, editors. Cardinal rate and rhythm. The Hague: Marinus Nijhoff; 1982. p. 507–23.CrossRefGoogle Scholar
  9. 9.
    Zwillich C, Deulin T, White D, et al. Bradycardia during sleep apnea. Characteristics and mechanisms. J Clin Invest. 1982;69(6):1286–92.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Frenneaux MP. Autonomic changes in patients with heart failure and in post myocardial infarction patients. Heart. 2004;90:1248–55.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Madsen B, Rasmussen V, Hansen J. Predictors of sudden death and death from pump failure in congestive heart failure are different. Analysis of 24 h Holter monitoring, clinical variables, blood chemistry, exercise test and radionuclide angiography. Int J Cardiol. 1997;58:1561–2.CrossRefGoogle Scholar
  12. 12.
    Guzzetti S, La Rovere MT, Pinna G, et al. Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure. Eur Heart J. 2005;26:357–62.CrossRefGoogle Scholar
  13. 13.
    Galinier M, Pathak A, Fourcade J, et al. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J. 2000;21:475–82.CrossRefGoogle Scholar
  14. 14.
    Grimm W, Hoffmann J, Menz V, et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol. 1996;77(15):1310–4.CrossRefGoogle Scholar
  15. 15.
    Ribuot C, Godin D, Couture R, Regoli D, Nadeau R. In vivo B2-receptor-mediated negative chronotropic effect of bradykinin in canine sinus node. Am J Physiol Heart Circ Physiol. 1993;265:H876–9.CrossRefGoogle Scholar
  16. 16.
    Srein R, Medeiros CM, Rosito GA, et al. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J Am Coll Cardiol. 2002;39(6):1033–8.CrossRefGoogle Scholar
  17. 17.
    Milanesi R, Baroscotti M, Gnecchi-Ruscone T, DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med. 2006;354:151–7.CrossRefGoogle Scholar
  18. 18.
    Alboni P, Menozzi C, Brignole M, Paparella N, et al. Effects of permanent pacemaker and oral theophylline in sick sinus syndrome. The THEOPACE study: a randomized controlled trial. Circulation. 1997;96:260–6.CrossRefGoogle Scholar
  19. 19.
    Scheinman MM, Thorburn D, Abbott JA. Use of atropine in patients with acute myocardial infarction and sinus bradycardia. Circulation. 1975;52:627–33.CrossRefGoogle Scholar
  20. 20.
    Spiridoula Vavetsi S, Nikolaou N, Tsarouhas K, et al. Consecutive administration of atropine and isoproterenol for the evaluation of asymptomatic sinus bradycardia. Europace. 2008;10(10):1176–81.CrossRefGoogle Scholar
  21. 21.
    Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol. 2008;51:e1–e62.CrossRefGoogle Scholar
  22. 22.
    Kistler PM, Sanders P, Fynn SP, Stevenson IH, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109–16.CrossRefGoogle Scholar
  23. 23.
    Barón-Esquivias G, Pedrote A, Cayuela A, Valle JI, Fernández JM, et al. Long-term outcome of patients with asystole induced by head-up tilt test. Eur Heart J. 2002;23:483–9.CrossRefGoogle Scholar
  24. 24.
    Goldman MJ. Principles of clinical electrocardiography. 12th ed. Los Altos: Lange Medical Publications; 1986. p. 224.Google Scholar
  25. 25.
    Batsford WP, Akhtar M, Caracta AR, et al. Effect of atrial stimulation site on electrophysiological properties of atrioventricular node in man. Circulation. 1974;50:283–92.CrossRefGoogle Scholar
  26. 26.
    Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–66.CrossRefGoogle Scholar
  27. 27.
    Steinbeck G, Hoffmann E. “True” atrial tachycardia. Eur Heart J. 1998;19(Suppl E):E10–9.Google Scholar
  28. 28.
    Ferrer MJ. The sick sinus syndrome in atrial disease. JAMA. 1968;206:645–6.CrossRefGoogle Scholar
  29. 29.
    Rubenstein JJ, Schulman CL, Yurchck PM, DeSanctis RW. Clinical spectrum of the sick sinus syndrome. Circulation. 1972;46:5–13.CrossRefGoogle Scholar
  30. 30.
    Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). J Am Coll Cardiol. 2003;42:1493–531.CrossRefGoogle Scholar
  31. 31.
    Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a statement from a joint expert group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001;22:1162–82.CrossRefGoogle Scholar
  32. 32.
    Huikuri HV, Poutiainen AM, Mäkikallio TH, et al. Dynamic behavior and autonomic regulation of ectopic atrial pacemakers. Circulation. 1999;100:1416–22.CrossRefGoogle Scholar
  33. 33.
    Poutiainen AM, Koistinen MJ, Airaksinen KE, et al. Prevalence and natural course of ectopic atrial tachycardia. Eur Heart J. 1999;20:694–700.CrossRefGoogle Scholar
  34. 34.
    Kalman JM, Olgin JE, Karch MR, et al. “Cristal tachycardias:” origin of right atrial tachycardias from the crista terminalis identified by intracardiac echocardiography. J Am Coll Cardiol. 1998;31:451–9.CrossRefGoogle Scholar
  35. 35.
    Tada H, Nogami A, Naito S, et al. Simple electrocardiographic criteria for identifying the site of origin of focal right atrial tachycardia. Pacing Clin Electrophysiol. 1998;21:2431–9.CrossRefGoogle Scholar
  36. 36.
    Hoffmann E, Reithmann C, Nimmermann P, et al. Clinical experience with electroanatomic mapping of ectopic atrial tachycardia. Pacing Clin Electrophysiol. 2002;25:49–56.CrossRefGoogle Scholar
  37. 37.
    Sippen Groenewegen A, Lesh MD, Rothinger FX, et al. Body surface mapping of counterclockwise and clockwise typical atrial flutter: a comparative analysis with endocardial activation sequence mapping. J Am Coll Cardiol. 2000;35:1276–87.CrossRefGoogle Scholar
  38. 38.
    Walsh EP, Saul JP, Hulse JE, et al. Transcatheter ablation of ectopic atrial tachycardia in young patients using radiofrequency current. Circulation. 1992;86:1138–46.CrossRefGoogle Scholar
  39. 39.
    Cossu SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic characteristics. Prog Cardiovasc Dis. 1998;41:51–63.CrossRefGoogle Scholar
  40. 40.
    Goya M, Lesaka Y, Takahashi A, et al. Radiofrequency catheter ablation for sinoatrial node re-entrant tachycardia: electrophysiologic features of ablation sites. Jpn Circ J. 1999;63:177–83.CrossRefGoogle Scholar
  41. 41.
    Goldenstein DS, Holmes C, Frabj SM, et al. Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation. 2002;106:2358–65.CrossRefGoogle Scholar
  42. 42.
    Romano SM, Lazzeri C, Chiostri M, Gensini GF. Beat-to-beat analysis of pressure wave morphology for pre-symptomatic detection of orthostatic intolerance during head-up tilt. J Am Coll Cardiol. 2004;44:1891–7.CrossRefGoogle Scholar
  43. 43.
    Low PA, Opfer-Gehrking TL, Textor SC, et al. Postural tachycardia syndrome (POTS). Neurology. 1995;45(Suppl 5):S19–25.Google Scholar
  44. 44.
    Grubb BP, Kosinski DJ, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during heart-up tilt table testing. Pacing Clin Electrophysiol. 1997;20:2205–12.CrossRefGoogle Scholar
  45. 45.
    Bush VE, Wight VL, Brown CM, Hainsworth R. Vascular responses to orthostatic stress in patients with postural tachycardia syndrome (POTS) in patients with low orthostatic tolerance, and in asymptomatic controls. Clin Auton Res. 2000;10:279–84.CrossRefGoogle Scholar
  46. 46.
    Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter modification of the sinus node for “inappropriate” sinus tachycardia. Circulation. 1995;92:2919–28.CrossRefGoogle Scholar
  47. 47.
    Mischke K, Stellbrink C, Hanrath P. Evidence of sinoatrial block as a curative mechanism in radiofrequency current ablation of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol. 2001;12:264–7.CrossRefGoogle Scholar
  48. 48.
    Man KC, Knight B, Tse HF, et al. Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation mapping. J Am Coll Cardiol. 2000;35:451–7.CrossRefGoogle Scholar
  49. 49.
    Sato T, Mitamura H, Murata M, et al. Electrophysiologic findings of a patient with inappropriate sinus tachycardia cured by selective radiofrequency catheter ablation. J Electrocardiol. 2000;33:381–6.CrossRefGoogle Scholar
  50. 50.
    Van Lieshout JJ, Wieling W, Karemaker JM, Eckberg DL. The vasovagal response. Clin Sci. 1991;81:575–86.CrossRefPubMedGoogle Scholar
  51. 51.
    Sander-Jensen K, Secher NH, Astrup A, et al. Hypotension induced by passive head-up tilt: endocrine and circulatory mechanisms. Am J Physiol. 1986;251:R742–8.PubMedGoogle Scholar
  52. 52.
    Morillo CA, Eckberg DL, Ellenbogen KA, et al. Vagal and sympathetic mechanisms in patients with orthostatic vasovagal syncope. Circulation. 1997;96:2509–13.CrossRefPubMedGoogle Scholar
  53. 53.
    Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.CrossRefPubMedGoogle Scholar
  54. 54.
    Prystowsky EN, Katz AM. Atrial fibrillation. In: Topol EJ, editor. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven; 1998. p. 1661.Google Scholar
  55. 55.
    Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2006;48:e149–246.CrossRefGoogle Scholar
  56. 56.
    Polontchouk L, Haefliger JA, Ebelt B, et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol. 2001;38:883–91.CrossRefGoogle Scholar
  57. 57.
    Pokharel S, van Geel PP, Sharma UC, et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation. 2004;110:3129–35.CrossRefGoogle Scholar
  58. 58.
    Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253–8.CrossRefGoogle Scholar
  59. 59.
    Maixent JM, Paganelli F, Scaglione J, et al. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:612–7.CrossRefGoogle Scholar
  60. 60.
    Tsai CF, Tai CT, Hsieh MH, et al. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation. Circulation. 2000;102:67–74.CrossRefPubMedGoogle Scholar
  61. 61.
    White CW, Kerber RE, Weiss HR, et al. The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res. 1982;51:205–15.CrossRefPubMedGoogle Scholar
  62. 62.
    Kamkin A, Kiseleva I, Wagner KD, et al. Mechanically induced potentials in atrial fibroblasts from rat hearts are sensitive to hypoxia/reoxygenation. Pflugers Arch. 2003;446:169–74.CrossRefPubMedGoogle Scholar
  63. 63.
    Schauerte P, Scherlag BJ, Pitha J, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation. 2000;102:2774–80.CrossRefPubMedGoogle Scholar
  64. 64.
    Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004;109:327–34.CrossRefPubMedGoogle Scholar
  65. 65.
    Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110:364–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Tsai CT, Lai LP, Hwang JJ, et al. Molecular genetics of atrial fibrillation. J Am Coll Cardiol. 2008;52:241–50.CrossRefPubMedGoogle Scholar
  67. 67.
    Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636–44.CrossRefPubMedGoogle Scholar
  68. 68.
    Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471–7.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Coromilas J. Obesity and atrial fibrillation: is one epidemic feeding the other? JAMA. 2004;292:2519–20.CrossRefPubMedGoogle Scholar
  70. 70.
    Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385–94.CrossRefPubMedGoogle Scholar
  71. 71.
    Israel CW, Gronefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004;43:47–52.CrossRefPubMedGoogle Scholar
  72. 72.
    Page R, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89:224–7.CrossRefPubMedGoogle Scholar
  73. 73.
    Page RL, Tilsch TW, Connolly SJ, et al. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141–5.CrossRefPubMedGoogle Scholar
  74. 74.
    Kerr CR, Boone J, Connolly SJ, et al. The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. Am J Cardiol. 1998;82:82 N–5 N.CrossRefGoogle Scholar
  75. 75.
    Olson JA, Fouts AM, Padanilam BJ, Prystowsky EN. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. J Cardiovasc Electrophysiol. 2007;18(5):473–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Vasamreddy CR, Dalal D, Dong J, et al. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 2006;17(2):134–9.CrossRefPubMedGoogle Scholar
  77. 77.
    AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.CrossRefGoogle Scholar
  78. 78.
    Hagens VE, Ranchor AV, Van Sonderen E. Bosker et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. Am Coll Cardiol. 2004;43(2):241–7.CrossRefGoogle Scholar
  79. 79.
    Van Gelder I, Hagens VE, Bosker HA, Kingma H, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.CrossRefPubMedGoogle Scholar
  80. 80.
    Opolski G, Torbicki A, Kosior DA, et al. Rate control vs. rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;26:476–86.CrossRefGoogle Scholar
  81. 81.
    Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet. 2000;356:1789–94.CrossRefPubMedGoogle Scholar
  82. 82.
    Roy DR, Nattel S, Wyse G, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.CrossRefPubMedGoogle Scholar
  83. 83.
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. Results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.CrossRefPubMedGoogle Scholar
  84. 84.
    Ebell MH. A systematic approach to managing warfarin doses. Fam Pract Manag. 2005;5:77–83.Google Scholar
  85. 85.
    O’Reilly RA. Anticoagulant, antithrombotic, and thrombolytic drugs. In: Gilman AG, Goodman LS, Rall TW, Murad F, editors. Goodman and Gilman’s: the pharmacological basis of therapeutics. 7th ed. New York: MacMillan Publishing; 1985. p. 1344–52.Google Scholar
  86. 86.
    Willenheimer R, Lechat P. New concepts in managing patients with chronic heart failure: the evolving importance of beta-blockade. Eur Heart J Suppl. 2006;8(Supp C):c3.CrossRefGoogle Scholar
  87. 87.
    Stein KM, Borer JS, Hochreiter C, et al. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. Am J Cardiol. 1994;74:906–11.CrossRefPubMedGoogle Scholar
  88. 88.
    Frey B, Heinz G, Binder T, et al. Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. Am Heart J. 1995;129:58–65.CrossRefPubMedGoogle Scholar
  89. 89.
    Atwood JE, Myers J, Sandhu S, et al. Optimal sampling interval to estimate heart rate at rest and during exercise in atrial fibrillation. Am J Cardiol. 1989;63:45–8.CrossRefPubMedGoogle Scholar
  90. 90.
    Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201–8.CrossRefPubMedGoogle Scholar
  91. 91.
    Donovan KD, Power BM, Hockings BE, et al. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995;75:693–7.CrossRefPubMedGoogle Scholar
  92. 92.
    Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722–7.CrossRefPubMedGoogle Scholar
  93. 93.
    Botto GL, Capucci A, Bonini W, et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol. 1997;58:55–61.CrossRefPubMedGoogle Scholar
  94. 94.
    Donovan KD, Dobb GJ, Coombs LJ, et al. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol. 1991;67:137–41.CrossRefPubMedGoogle Scholar
  95. 95.
    Bertini G, Conti A, Fradella G, et al. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med. 1990;8:15–20.CrossRefPubMedGoogle Scholar
  96. 96.
    Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997;96:4298–306.CrossRefPubMedGoogle Scholar
  97. 97.
    Guo GB, Ellenbogen KA, Wood MA, et al. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol. 1996;27:1083–9.CrossRefPubMedGoogle Scholar
  98. 98.
    Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130–6.CrossRefPubMedGoogle Scholar
  99. 99.
    Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol. 1997;29:385–90.CrossRefPubMedGoogle Scholar
  100. 100.
    Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J. 1999;137:1062–9.CrossRefGoogle Scholar
  101. 101.
    Sedgwick ML, Lip G, Rae AP, et al. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol. 1995;49:159–66.CrossRefGoogle Scholar
  102. 102.
    Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341:857–65.CrossRefGoogle Scholar
  103. 103.
    Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385–90.CrossRefGoogle Scholar
  104. 104.
    Kochiadakis GE, Igoumenidis NE, Solomou MC, et al. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol. 1999;83:58–61.CrossRefGoogle Scholar
  105. 105.
    Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079–82.CrossRefGoogle Scholar
  106. 106.
    Peuhkurinen K, Niemela M, Ylitalo A, et al. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol. 2000;85:462–5.CrossRefGoogle Scholar
  107. 107.
    Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–72.CrossRefGoogle Scholar
  108. 108.
    Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d, l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d, l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270–7.CrossRefGoogle Scholar
  109. 109.
    Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133:441–6.CrossRefGoogle Scholar
  110. 110.
    Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932–9.CrossRefGoogle Scholar
  111. 111.
    Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther. 1996;10:145–52.CrossRefGoogle Scholar
  112. 112.
    Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med. 2000;342:913–20.CrossRefGoogle Scholar
  113. 113.
    Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart. 2000;84:251–7.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Chun SH, Sager PT, Stevenson WG, et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995;76:47–50.CrossRefGoogle Scholar
  115. 115.
    The AFFIRM. First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42:20–9.CrossRefGoogle Scholar
  116. 116.
    Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003;91:15D–26D.CrossRefGoogle Scholar
  117. 117.
    Niebauer MJ, Brewer JE, Chung MK, et al. Comparison of the rectilinear biphasic waveform with the monophasic damped sine waveform for external cardioversion of atrial fibrillation and flutter. Am J Cardiol. 2004;93:1495–9.CrossRefGoogle Scholar
  118. 118.
    Prasad SM, Maniar HS, Camillo CJ, et al. The Cox Maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg. 2003;126:1822–7.CrossRefGoogle Scholar
  119. 119.
    McCarthy PM, Gillinov AM, Castle L, et al. The Cox-Maze procedure: The Cleveland Clinic experience. Semin Thorac Cardiovasc Surg. 2000;12:25–9.CrossRefGoogle Scholar
  120. 120.
    Raanani E, Albage A, David TE, et al. The efficacy of the Cox/Maze procedure combined with mitral valve surgery: a matched control study. Eur J Cardiothorac Surg. 2001;19:438–42.CrossRefGoogle Scholar
  121. 121.
    Schaff HV, Dearani JA, Daly RC, et al. Cox-Maze procedure for atrial fibrillation: Mayo Clinic experience. Semin Thorac Cardiovasc Surg. 2000;12:30–7.CrossRefGoogle Scholar
  122. 122.
    Khargi K, Hutten BA, Lemke B, Deneke T. Surgical treatment of atrial fibrillation; a systematic review. Eur J Cardiothorac Surg. 2005;27:258–65.CrossRefGoogle Scholar
  123. 123.
    Kottkamp H, Hindricks G, Autschbach R, et al. Specific linear left atrial lesions in atrial fibrillation: intraoperative radiofrequency ablation using minimally invasive surgical techniques. J Am Coll Cardiol. 2002;40:475–80.CrossRefGoogle Scholar
  124. 124.
    Salenger R, Lahey SJ, Saltman AE. The completely endoscopic treatment of atrial fibrillation: report on the first 14 patients with early results. Heart Surg Forum. 2004;7:E555–8.CrossRefGoogle Scholar
  125. 125.
    Swartz JF, Pellersels G, Silvers J, et al. A catheter-based curative approach to atrial fibrillation in humans (abstract). Circulation. 1994;90(4):I-335.Google Scholar
  126. 126.
    Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Europace. 2007;9:335–79.CrossRefGoogle Scholar
  127. 127.
    Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293:2634–40.CrossRefGoogle Scholar
  128. 128.
    Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006;354:934–41.CrossRefGoogle Scholar
  129. 129.
    Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation for the Cure of Atrial Fibrillation Study). Eur Heart J. 2006;27:216–21.CrossRefGoogle Scholar
  130. 130.
    Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006;48:2340–7.CrossRefGoogle Scholar
  131. 131.
    Jais P, Cauchemez B, MacLe L, et al. Atrial fibrillation ablation vs antiarrhythmic drugs: a multicenter randomized trial (abstract). Heart Rhythm. 2006;3(Suppl):1126.CrossRefGoogle Scholar
  132. 132.
    Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111:1100–5.CrossRefGoogle Scholar
  133. 133.
    Jayam VK, Dong J, Vasamreddy CR, Lickfett L, et al. Atrial volume reduction following catheter ablation of atrial fibrillation and relation to reduction in pulmonary vein size: an evaluation using magnetic resonance angiography. J Interv Card Electrophysiol. 2005;13:107–14.CrossRefGoogle Scholar
  134. 134.
    Tsao HM, Wu MH, Huang BH, et al. Morphologic remodeling of pulmonary veins and left atrium after catheter ablation of atrial fibrillation: insight from long-term follow-up of three-dimensional magnetic resonance imaging. J Cardiovasc Electrophysiol. 2005;16:7–12.CrossRefGoogle Scholar
  135. 135.
    Lemola K, Desjardins B, Sneider M, et al. Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. Heart Rhythm. 2005;2:923–8.CrossRefGoogle Scholar
  136. 136.
    Verma A, Kilicaslan F, Adams JR, et al. Extensive ablation during pulmonary vein antrum isolation has no adverse impact on left atrial function: an echocardiography and cine computed tomography analysis. J Cardiovasc Electrophysiol. 2006;17:741–6.CrossRefGoogle Scholar
  137. 137.
    Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol. 2004;43:1004–9.CrossRefGoogle Scholar
  138. 138.
    Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373–83.CrossRefGoogle Scholar
  139. 139.
    Tondo C, Mantica M, Russo G, et al. Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function. Pacing Clin Electrophysiol. 2006;29:962–70.CrossRefGoogle Scholar
  140. 140.
    Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778–85.CrossRefGoogle Scholar
  141. 141.
    Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary vein foci. Circulation. 2000;101(12):1409–17.CrossRefGoogle Scholar
  142. 142.
    Feinberg MS, Waggoner AD, Kater KM, Cox JL, Lindsay BD, Perez JE. Restoration of atrial function after the maze procedure for patients with atrial fibrillation. Assessment by Doppler echocardiography. Circulation. 1994;90(5 Pt 2):II285–92.Google Scholar
  143. 143.
    Prasad SM, Maniar HS, Camillo CJ, et al. The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg. 2003;126:1822–8.CrossRefGoogle Scholar
  144. 144.
    Ninet J, Roques X, Seitelberger R, et al. Surgical ablation of atrial fibrillation with off-pump, epicardial, high-intensity focused ultrasound: results of a multicenter trial. J Thorac Cardiovasc Surg. 2005;130:803–9.CrossRefGoogle Scholar
  145. 145.
    Pruitt JC, Lazzara RR, Dworkin GH, Badhwar V, Kuma C, Ebra G. Totally endoscopic ablation of lone atrial fibrillation: initial clinical experience. Ann Thorac Surg. 2006;81:1325–30.CrossRefGoogle Scholar
  146. 146.
    Wolf RK, Schneeberger EW, Osterday R, et al. Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg. 2005;130:797–802.CrossRefGoogle Scholar
  147. 147.
    Melby SJ, Zierer A, Bailey MS, et al. A new era in the surgical treatment of atrial fibrillation: the impact of ablation technology and lesion set on procedural efficacy. Ann Surg. 2006;244:583–92.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Chen SA, Chiang CE, Wu TJ, et al. Radiofrequency catheter ablation of common atrial flutter: comparison of electrophysiologically guided focal ablation technique and linear ablation technique. J Am Coll Cardiol. 1996;27:860–8.CrossRefGoogle Scholar
  149. 149.
    Natale N, Newby KH, Pisanó E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35:1898–904.CrossRefGoogle Scholar
  150. 150.
    McAnulty JH, Rahimtoola SH, Murphy E, et al. Natural history of “high-risk” bundle-branch block: final report of a prospective study. N Engl J Med. 1982;307:137–43.CrossRefGoogle Scholar
  151. 151.
    Dhingra RC, Wyndham C, Bauernfeind R, et al. Significance of block distal to the His bundle induced by atrial pacing in patients with chronic bifascicular block. Circulation. 1979;60:1455–64.CrossRefGoogle Scholar
  152. 152.
    Scheinman MM, Peters RW, Modin G, et al. Prognostic value of infranodal conduction time in patients with chronic bundle branch block. Circulation. 1977;56:240–4.CrossRefGoogle Scholar
  153. 153.
    Denes P, Levy L, Pick A, Rosen KM. The incidence of typical and atypical A-V Wenckebach periodicity. Am Heart J. 1975;89:26–31.CrossRefGoogle Scholar
  154. 154.
    Meytes I, Kaplinsky E, Yahini JH, et al. Wenckebach A-V block: a frequent feature following heavy physical training. Am Heart J. 1975;90:426–30.CrossRefGoogle Scholar
  155. 155.
    Shaw DB, Kekwick CA, Veale D, et al. Survival in second degree atrioventricular block. Br Heart J. 1985;53:587–93.CrossRefPubMedPubMedCentralGoogle Scholar
  156. 156.
    Narula OS, Smet P. Wenckebach and Mobitz type II A-V block due to block within the His bundle and bundle branches. Circulation. 1970;41:947–65.CrossRefGoogle Scholar
  157. 157.
    Wm M, Klein LS. Sinus nodal dysfunction and atrioventricular conduction disturbances. In: Naccarelli GV, editor. Cardiac arrhythmias: a practical approach. Mt. Kisco: Futura; 1991. p. 243–82.Google Scholar
  158. 158.
    Damato AN, Lau SH, Helfant RH, et al. A study of heart block in man using His bundle recordings. Circulation. 1969;39:297–305.CrossRefGoogle Scholar
  159. 159.
    Rosen KM, Gunnar RM, Rahimtoola SH. Site and type of second degree AV block. Chest. 1972;61:99–100.CrossRefGoogle Scholar
  160. 160.
    MacMurray FG. Stokes-Adams disease. New Eng J Med. 1957;256:643–52.CrossRefPubMedPubMedCentralGoogle Scholar
  161. 161.
    Lepeschkin E. The electrocardiographic diagnosis of bilateral bundle branch block in relation to heart block. Prog Cardiovasc Dis. 1964;6:445–51.CrossRefPubMedPubMedCentralGoogle Scholar
  162. 162.
    Pinsky W, Gillette PC, Garson AT. Diagnosis, management and long term results of patients with complete atrioventricular block. Pediatrics. 1982;69:728–33.PubMedPubMedCentralGoogle Scholar
  163. 163.
    Zipes DP, Ackerman MJ, Estes MIII, et al. Task force 7: arrhythmias. J Am Coll Cardiol. 2005;45:1354–63.CrossRefPubMedPubMedCentralGoogle Scholar
  164. 164.
    Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG era. J Card Fail. 2006;12(5):343–6.CrossRefGoogle Scholar
  165. 165.
    Josephson ME, Kastor JA. Supraventricular tachycardia: mechanisms and management. Ann Intern Med. 1977;87:346–58.CrossRefGoogle Scholar
  166. 166.
    Akhtar M. Supraventricular tachycardias. Electrophysiologic mechanisms, diagnosis, and pharmacologic therapy. In: Josephson ME, HJJ W, editors. Tachycardias: mechanisms, diagnosis, treatment. Philadelphia: Lea & Febiger; 1984. p. 137.Google Scholar
  167. 167.
    Josephson ME, Seides SE, Batsford WB, et al. The effects of carotid sinus pressure in reentrant paroxysmal supraventricular tachycardia. Am Heart J. 1974;88:694–5.CrossRefGoogle Scholar
  168. 168.
    DiMarco JP, Sellers TD, Bere RM, West GA. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardias. Circulation. 1983;68:1254–63.CrossRefGoogle Scholar
  169. 169.
    Belhassen B, Glick A, Laniado S. Comparative clinical and electrophysiologic effects of adenosine triphosphate and verapamil on paroxysmal reciprocating junctional tachycardia. Circulation. 1988;77:795–805.CrossRefGoogle Scholar
  170. 170.
    Belhassen B, Pelleg A. Acute management of paroxysmal supraventricular tachycardia: verapamil, adenosine triphosphate or adenosine? Am J Cardiol. 1984;54:225–7.CrossRefGoogle Scholar
  171. 171.
    Stevenson WG, Delacretaz E. Electrophysiology: radiofrequency catheter ablation of ventricular tachycardia. Heart. 2000;84:553–9.CrossRefPubMedPubMedCentralGoogle Scholar
  172. 172.
    Kuchar DL, Ruskin JN, Garan H. Electrocardiographic localization of the site of origin of ventricular tachycardia in patients with prior myocardial infarction. J Am Coll Cardiol. 1989;13:893–903.CrossRefGoogle Scholar
  173. 173.
    Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971;44:130–42.CrossRefGoogle Scholar
  174. 174.
    Flemming M, Oral H, Kim M, et al. Electrocardiographic predictors of successful ablation of tachycardia or bigeminy arising in the right ventricular outflow tract. Am J Cardiol. 1999;84:1266–8.CrossRefGoogle Scholar
  175. 175.
    Friedman PA, Asirvatham SJ, Grice S, et al. Noncontact mapping to guide ablation of right ventricular outflow tract tachycardia. J Am Coll Cardiol. 2002;39:1808–12.CrossRefPubMedGoogle Scholar
  176. 176.
    Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol. 2005;45:125–65.CrossRefGoogle Scholar
  177. 177.
    Kennedy HL, Underhill SJ. Frequent or complex ventricular ectopy in apparently healthy subjects. Am J Cardiol. 1976;38:141–8.CrossRefPubMedGoogle Scholar
  178. 178.
    Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984;69:250–8.CrossRefPubMedGoogle Scholar
  179. 179.
    The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331–6.CrossRefGoogle Scholar
  180. 180.
    Kotler MN, Tabatznik B, Mower MM, Tominaga S. Prognostic significance of ventricular ectopic beats with respect to sudden death in the late postinfarction period. Circulation. 1973;47:959–66.CrossRefPubMedGoogle Scholar
  181. 181.
    Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol. 1985;55:146–51.CrossRefPubMedGoogle Scholar
  182. 182.
    Prystowsky EN, Heger JJ, Zipes DP. The recognition and treatment of patients at risk for sudden death. In: Eliot RS, Saenz A, Forker AD, editors. Cardiac emergencies. Mt. Kisco: Futura Publishing; 1982. p. 353–84.Google Scholar
  183. 183.
    Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med. 1977;297:750–7.CrossRefPubMedGoogle Scholar
  184. 184.
    Moss AJ, David HT, DeCamilla J, Bayer LW. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation. 1979;60:988–97.CrossRefGoogle Scholar
  185. 185.
    Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. Circulation. 1993;87:312–22.CrossRefGoogle Scholar
  186. 186.
    Buxton AE, Fisher JD, Josephson ME, et al. and the MUSTT Investigators. Prevention of sudden death in patients with coronary artery disease. Prog Cardiovasc Dis. 1993;36:215–26.CrossRefPubMedGoogle Scholar
  187. 187.
    Epstein AW, Bigger JT Jr, Wyse DG, et al. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol. 1991;18:14–9.CrossRefPubMedGoogle Scholar
  188. 188.
    Greene HL, Roden DM, Katz RJ, et al. The Cardiac Arrhythmia Suppression Trial: first CAST then CAST-II. J Am Coll Cardiol. 1992;19:894–8.CrossRefPubMedGoogle Scholar
  189. 189.
    Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349:667–73.CrossRefPubMedGoogle Scholar
  190. 190.
    Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT (for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators). Lancet. 1997;349:675–82.CrossRefPubMedGoogle Scholar
  191. 191.
    Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation. 1993;23:1333–41.Google Scholar
  192. 192.
    Rodriguez LM, Smeets JL, Timmermans C, et al. Predictors of successful ablation of right- and left-sided idiopathic ventricular tachycardia. Am J Cardiol. 1997;79(3):309–14.CrossRefPubMedGoogle Scholar
  193. 193.
    Belhassen B, Rotmensch HH, Laniado S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J. 1981;46:679–82.CrossRefPubMedPubMedCentralGoogle Scholar
  194. 194.
    Lin FC, Finley CD, Rahimtoola SH, Wu D. Idiopathic paroxysmal ventricular tachycardia with a QRS pattern of right bundle branch block and left axis deviation: a unique clinical entity with specific properties. Am Cardiol. 1983;52:95–100.CrossRefGoogle Scholar
  195. 195.
    Ohe T, Aihara N, Kamakura S, Kurita T, Shiniizu W, Shimomura K. Long-term outcome of verapamil-sensitive sustained left ventricular tachycardia in patients without structural heart disease. J Am Coil Cardiol. 1995;25:54–8.CrossRefGoogle Scholar
  196. 196.
    Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512–20.CrossRefPubMedGoogle Scholar
  197. 197.
    Daliento L, Rizzoli G, Thiene G, et al. Diagnostic accuracy of right ventriculography in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 1997;66:741–5.CrossRefGoogle Scholar
  198. 198.
    Ricci C, Longo R, Pagnan L, et al. Magnetic resonance imaging in right ventricular dysplasia. Am J Cardiol. 1992;70:1589–95.CrossRefPubMedGoogle Scholar
  199. 199.
    Blake LM, Scheinman MM, Higgins CB. MR features of arrhythmogenic right ventricular dysplasia. Am J Radiol. 1994;162:809–12.Google Scholar
  200. 200.
    Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. New Engl J Med. 2009;360:1075–84.CrossRefGoogle Scholar
  201. 201.
    Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48:1064–108.CrossRefGoogle Scholar
  202. 202.
    Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation. 1993;87:312–22.CrossRefGoogle Scholar
  203. 203.
    Blnck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol. 1993;4:23–62.CrossRefGoogle Scholar
  204. 204.
    Delacretaz E, Stevenson WG, Ellison KE, et al. Mapping and radiofrequency catheter ablation of the tree types of sustained monomorphic ventricular tachycardias in nonischemic heart disease. J Cardiovasc Electrophysiol. 2000;1:11–7.CrossRefGoogle Scholar
  205. 205.
    Sosa E, Scanavacca M, D’Avila A, et al. Endocardial and epicardial ablation guided by nonsurgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol. 1998;9:229–39.CrossRefGoogle Scholar
  206. 206.
    The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.CrossRefGoogle Scholar
  207. 207.
    Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.CrossRefGoogle Scholar
  208. 208.
    Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–54.CrossRefGoogle Scholar
  209. 209.
    Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1993;341:1882–90.CrossRefGoogle Scholar
  210. 210.
    Moss AJ, Jackson Hall W, Canom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–40.CrossRefGoogle Scholar
  211. 211.
    Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.CrossRefGoogle Scholar
  212. 212.
    Moss AJ, Zareba W, Jackson Hall W, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.CrossRefGoogle Scholar
  213. 213.
    Akhtar M, Shenasa M, Jazayeri M, Caceres J. Wide QRS complex tachycardia. Reappraisal of a common clinical problem. Ann Intern Med. 1988;109:905–12.CrossRefGoogle Scholar
  214. 214.
    Wellens HJ, Bar FW. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med. 1978;64:27–33.CrossRefGoogle Scholar
  215. 215.
    Kindwall KE, Brown J, Josephson ME. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. Am J Cardiol. 1988;61:1279–83.CrossRefGoogle Scholar
  216. 216.
    Griffith MJ, de Belder MA, Linker NJ, Ward DE. Multivariate analysis to simplify the differential diagnosis of broad complex tachycardia. Br Heart J. 1991;66:166–74.CrossRefPubMedPubMedCentralGoogle Scholar
  217. 217.
    Brugada P, Brugada J, Mont L, Smeets J. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation. 1991;83:1649–59.CrossRefGoogle Scholar
  218. 218.
    Alberca T, Almendral J, Sanz P, Almazan A, Cantalapiedra JL. Evaluation of the specificity of morphological electrocardiographic criteria for the differential diagnosis of wide QRS complex tachycardia in patients with intraventricular conduction defects. Circulation. 1997;96:3527–33.CrossRefGoogle Scholar
  219. 219.
    Vereckei A, Duray G, Szénási G, Altmose GT, Miller JM. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J. 2007;28:589–600.CrossRefGoogle Scholar
  220. 220.
    Dendi R, Josephson ME. A new algorithm in the differential diagnosis of wide complex tachycardia. Eur Heart J. 2007;28:525–6.CrossRefGoogle Scholar
  221. 221.
    Roberts R. Genomics and cardiac arrhythmias. J Am Coll Cardiol. 2006;47:9–21.CrossRefGoogle Scholar
  222. 222.
    Kaab S, Schulze-Bahr E. Susceptibility genes and modifiers for cardiac arrhythmias. Cardiovasc Res. 2005;6:397–413.CrossRefGoogle Scholar
  223. 223.
    Wiesfeld ACP, Hemels MEW, VanTintelen P, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. Genetic aspects of atrial fibrillation. Cardiovasc Res. 2005;67:414–8.CrossRefGoogle Scholar
  224. 224.
    Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). J Am Coll Cardiol. 2003;42:1687–713.CrossRefGoogle Scholar
  225. 225.
    Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. Am J Cardiol. 1989;63:1258–65.CrossRefGoogle Scholar
  226. 226.
    Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510–5.CrossRefGoogle Scholar
  227. 227.
    Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660–6.CrossRefGoogle Scholar
  228. 228.
    Wang K, Asinger RW, Marriott HJL. ST-Segment elevation in conditions other than acute myocardial infarction. N Engl J Med. 2003;349:2128–35.CrossRefGoogle Scholar
  229. 229.
    Goldenberg I, Moss AJ, Zareba W. QT Interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol. 2006;17:333–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Blair Foreman
    • 1
  1. 1.Cardiovascular Medicine, Midwest Cardiovascular Research FoundationDavenportUSA

Personalised recommendations